Elinzanetant showed significant efficacy in reducing VMS frequency and severity, with rapid symptom improvement compared to ...

Panelists discuss the methodologies of the OASIS 1, 2, and 3 trials that investigated elinzanetant, highlighting key findings ...

Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.

An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.

Forecasts indicate a drastic increase in US obesity rates in the next 25 years, emphasizing the need for comprehensive public ...

FoundationOne Liquid CDx is now FDA-approved to identify mNSCLC patients with MET exon 14 skipping alterations for tepotinib ...

Of the 518 hospitals that had at least 10 eligible discharges, only 11 of them prescribed SGLT2 inhibitors to more than half ...

The FINEARTS-HF trial offered novel clinical insights as one of the few cardiovascular trials to feature such a great proportion of female participants.

Muvalaplin, an oral drug, significantly reduces Lp(a) levels by disrupting apo(a) and apoB bonding, achieving up to 85.5% reduction in a phase 2 study. Lp(a) is a genetically driven cardiovascular ...

New discoveries in atherosclerosis pathways have shed light on the active mechanisms in other diseases such as chronic kidney disease (CKD) and HIV, paving the way for furture therapeutics.

The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse ...

A delay in the FDA decision for NT-501 could leave those with macular telangiectasia (MacTel) without any form of treatment ...